Valiant Laboratories reported a standalone net profit of ₹9.48 crore for the quarter ended June 30, 2026, a 422% increase from ₹1.82 crore in the corresponding period of FY25. The Mumbai-based pharmaceutical company also saw its revenue from operations surge 44% year-on-year to ₹74.27 crore, up from ₹51.68 crore in Q1FY26. Consolidated net profit turned positive at ₹21.10 crore, reversing a loss of ₹3.27 crore recorded in the prior year quarter.

The results were reviewed by the Audit Committee and approved by the Board of Directors in a meeting held on August 10, 2026. The financial statements were prepared in accordance with Indian Accounting Standards (IndAS) prescribed under Section 133 of the Companies Act, 2013, and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company published these audited results in Financial Express and Mumbai Lakshadeep on August 12, 2026, as required under Regulation 30 and Regulation 47 of SEBI LODR.

Financial Performance

Standalone earnings per share (EPS) stood at ₹1.75 for the quarter, compared to ₹0.42 in Q1FY26. On a consolidated basis, EPS was ₹3.89, improving from ₹0.42 in the previous year. The company’s paid-up equity share capital remained unchanged at ₹54.31 crore.

What the Numbers Show

The divergence between standalone and consolidated performance highlights significant operational leverage in the group structure. While standalone net profit before tax grew five-fold to ₹12.73 crore, consolidated pre-tax profit surged more than ten-fold to ₹26.19 crore. This suggests that subsidiaries or associates contributed disproportionately to the top-line growth, which rose 145% on a consolidated basis compared to 44% standalone. The reversal of consolidated losses into a substantial profit indicates improved efficiency or scale benefits across the group entities during the quarter.

Valiant Laboratories Limited has authorized a ₹60 crore capital injection into its wholly owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL), to fund working capital and general corporate purposes. The Board of Directors approved the investment on August 10, 2026, alongside key governance changes including the re-appointment of Managing Director Santosh Vora and Independent Director Sonal Vira, and a strategic shift of the registered office from Mumbai to Palghar. This move strengthens the financial base of the company’s high-growth specialty chemicals arm without diluting equity control.

The investment will be executed in one or more tranches over the next 12 months, subject to VASPL’s fund requirements. Valiant Laboratories will subscribe to 1% Optionally Convertible Redeemable Preference Shares in the subsidiary. As VASPL is a related party, the transaction is conducted at arm’s length in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The parent company retains 100% shareholding, ensuring no change in the equity structure.

Leadership and Governance Updates

The Board also approved several directorship changes, all subject to Special Resolution approval at the ensuing Annual General Meeting:

• Santosh Vora: Re-appointed as Managing Director for five years, effective February 06, 2027. He holds a PGPM from ISB and has over 8 years of experience in the chemical and pharmaceutical industry.
• Sonal Vira: Re-appointed as Independent Director for a second five-year term, effective February 16, 2027. She is a Chartered Accountant with over 15 years of experience in corporate banking.
• Shantilal Vora: Continuation of directorship as Non-Executive Non-Independent Director upon attaining 75 years of age, effective November 05, 2027, in compliance with Regulation 17(1A) of the Listing Regulations.

Operational Restructuring

Valiant Laboratories approved shifting its registered office from Mulund, Mumbai, to Plot No. L-13, L-28, L-28(Pt), L-29 & L-30, MIDC Tarapur, Boisar, Palghar, Maharashtra - 401506. This change shifts jurisdiction from the Registrar of Companies, Mumbai-I, to Mumbai-II (Navi Mumbai). Concurrently, a new corporate office will open at 701, Tower B, Embassy 247 Park, LBS Road, Vikhroli (West), Mumbai, to handle administrative, management, finance, and secretarial functions.

VASPL Financial Performance

VASPL, incorporated on July 08, 2022, manufactures specialty chemicals including acetic anhydride, ketene, and diketene derivatives. The subsidiary has demonstrated rapid revenue growth since inception.

As of March 31, 2026, VASPL reported a net worth of ₹15,618.41 Lakh. The substantial increase in turnover from ₹2.02 Lakh in FY25 to ₹4,164.86 Lakh in FY26 indicates that the subsidiary has scaled operations significantly, justifying the need for additional working capital support from the parent company.

What the Numbers Show

The financial trajectory of VASPL highlights a pivot from early-stage setup to active commercial operations. With turnover jumping from negligible levels in FY24 to over ₹41 crore in FY26, the subsidiary has become a material part of the group’s operational footprint. The ₹60 crore investment represents a strategic allocation of capital to sustain this growth momentum, particularly given that VASPL’s net worth stands at approximately ₹156 crore. This suggests the parent company is leveraging its balance sheet to optimize the capital structure of its high-growth specialty chemicals arm without diluting equity ownership.